Good Distribution Practice (GDP): Safeguarding Medicinal Integrity Across the Supply Chain 

09 Dec 2025

Good Distribution Practice (GDP) defines the minimum standards required to ensure that the quality, safety, and traceability of medicinal products are preserved throughout the supply chain. For TS Quality & Engineering, GDP is not just a regulatory requirement—it’s a cornerstone of our commitment to public health, operational transparency, and global compliance excellence. 

In the lifecycle of a medicinal product, distribution is often overlooked—but it is where quality meets reality. From the moment a medicine leaves the manufacturing site to its arrival at a pharmacy or hospital, its safety, efficacy, and traceability must remain intact. This is the domain of Good Distribution Practice (GDP)—a regulatory framework that ensures every link in the supply chain upholds the standards that protect patients. 

To strengthen industry alignment, it is important to clarify that GDP specifically applies to medicinal products (including APIs and excipients) and does not extend to medical devices, cosmetics, or dietary supplements unless legally classified as medicinal products. 

At TS Quality & Engineering, we view GDP not just as a compliance obligation, but as a strategic safeguard. It is the invisible infrastructure behind every safe dose delivered. 

Why GDP Matters: A System’s View 

GDP is a regulatory framework that sets minimum standards for the wholesale distribution of medicinal products. It governs how medicines are stored, transported, and handled to prevent degradation, contamination, or misdelivery. GDP also applies to active pharmaceutical ingredients (APIs) and excipients, ensuring that raw materials used in production meet the same rigorous standards. For TSQ&E, GDP is not just about compliance—it’s about building resilient systems that deliver quality without compromise. 

GDP ensures that: 

•  Medicines are authorized under EU legislation 

•  Storage and transport conditions preserve product integrity 

•  Cross-contamination is prevented 

•  Inventory turnover is adequate 

•  Products reach the correct recipient promptly 

•  Faulty products can be traced and recalled efficiently 

This applies not only to finished medicinal products but also to active pharmaceutical ingredients (APIs) and excipients used in manufacturing. 

GDP also reinforces quality governance by mandating well-defined roles, responsibilities, and competency requirements across the distribution chain. This includes ensuring that staff handling medicinal products are trained, qualified, and fully aware of their obligations within the GDP framework. 

Roles & Responsibilities Under GDP 

A foundational requirement of GDP is the appointment of a Responsible Person (RP), who is accountable for ensuring GDP compliance, oversight of deviations, supervision of training, qualification of suppliers, and communication with competent authorities. The RP must maintain ongoing training, demonstrate technical competence, and ensure that delegated tasks are appropriately supervised. 

Management teams must also establish clear organizational structures, define accountability for distribution activities, and maintain an active quality culture aligned with GDP expectations. 

Regulatory Landscape Post-COVID-19 

Following the WHO’s May 2023 declaration ending the COVID-19 public health emergency, the European Medicines Agency (EMA), European Commission, and Heads of Medicines Agencies (HMA) phased out temporary regulatory flexibilities: 

•  GDP certificate extensions granted during the pandemic will expire by end of 2024 

• National competent authorities (NCAs) have resumed on-site inspections 

• Remote assessments and international inspections helped reduce backlogs 

• From 2025, certificate validity will be determined case-by-case by NCAs 

TSQ&E advises clients to proactively engage with their issuing authorities to confirm certificate status and inspection readiness. 

Inspections have increasingly focused on temperature-controlled logistics, falsified medicines prevention, strengthened supply chain documentation, and continuous monitoring of outsourced activities—highlighting the need for robust, risk-based compliance. 

Legal Framework & Guidance 

GDP requirements are embedded in European legislation, including Directive 2001/83/EC and Regulation 2019/6. These are supported by EU guidelines for both finished medicinal products and active substances. The GMP/GDP Inspectors Working Group provides interpretive guidance through Q&As and harmonised procedures. TSQ&E ensures that clients understand not just the letter of the law, but its operational implications—translating legal frameworks into actionable compliance systems. 

GDP requirements are codified under: 

• Directive 2001/83/EC 

• Regulation 2019/6 (Veterinary Medicines) 

• EU Guidelines on GDP for Medicinal Products for Human Use 

• EU Guidelines on GDP for Active Substances 

The GMP/GDP Inspectors Working Group provides interpretive Q&As and harmonised procedures to support consistent implementation across Member States. 

To support global distribution networks, it is essential to interpret GDP alongside GMP requirements, serialization laws, national guidelines, and anti-falsification legislation. This integrated understanding reduces compliance risks in multi-jurisdictional supply chains. 

Authorization & Oversight 

Any organization engaged in wholesale distribution within the European Economic Area (EEA) must hold a Wholesale Distribution Authorization (WDA) issued by their national authority. This includes importers, API distributors, and parallel distributors. Manufacturers distributing their own authorized products are exempt from separate authorization but must still comply with GDP principles. TSQ&E supports clients in securing authorisations, preparing for inspections, and maintaining robust documentation aligned with EU expectations. 

Entities engaged in wholesale distribution within the European Economic Area (EEA) must: 

• Hold a Wholesale Distribution Authorization (WDA) from their national competent authority 

• Undergo regular inspections to verify GDP compliance 

• Register with NCAs if importing or distributing APIs 

• Comply with GDP even when operating under parallel distribution or manufacturing authorisations 

Organizations must also maintain change-control processes to assess and approve changes related to storage sites, transport routes, logistics providers, or critical equipment—ensuring that GDP compliance is preserved through every operational transition. 

TSQ&E supports clients in preparing for inspections, maintaining documentation, and aligning operations with GDP expectations. 

EudraGMDP Database: Transparency in Action 

The EudraGMDP database is the EU’s central repository for GDP-related compliance data. It includes valid WDAs, GDP certificates, non-compliance statements, and GMP inspection records. TSQ&E uses this tool to verify supplier credentials, audit readiness, and regulatory history—ensuring transparency and trust across the supply chain. For clients, it’s a vital resource for due diligence and risk mitigation. 

The EudraGMDP database provides public access to: 

• Valid WDAs and GDP certificates 

• Registered API importers and distributors 

• Non-compliance statements 

• GMP-related inspection data 

Regular monitoring of partner credentials, certificate expirations, inspection histories, and non-compliance notices is essential for mitigating supply chain risks and ensuring continuity of operations 

TSQ&E uses this resource to benchmark client readiness, verify supplier credentials, and support regulatory due diligence. 

Harmonization Through Union Procedures 

To ensure consistency across Member States, EMA maintains a Compilation of Union Procedures that standardizes inspection protocols, defect reporting, and recall coordination. These procedures facilitate cross-border cooperation and enable swift regulatory action when quality risks emerge. TSQ&E helps clients align with these harmonized expectations, ensuring that their operations are inspection-ready regardless of jurisdiction. 

EMA’s Compilation of Union Procedures standardizes: 

• Inspection protocols 

• Quality defect reporting 

• Rapid alerts and recall coordination 

• Exchange of inspection findings across Member States 

Templates and procedural forms are available to inspectorates and stakeholders to streamline compliance workflows. Harmonized defect classification, cross-border rapid alerts, and coordinated recalls enhance patient safety and improve the efficiency of incident response across EU markets. 

TSQ&E Perspective: Operationalizing GDP 

At TS Quality & Engineering, we go beyond theory to help clients embed GDP into daily operations. Our services include cold chain validation, SOP development, environmental monitoring, supplier qualification, and mock audits. We tailor solutions to each client’s sector and scale—whether they’re distributing temperature-sensitive biologics or high-volume generics. Our goal is to make GDP not just achievable, but sustainable and scalable. 

At TS Quality & Engineering, we help clients translate GDP principles into actionable systems: 

• Cold chain validation and transport mapping 

• SOP development for traceability and recall 

• Risk-based storage audits and environmental monitoring 

• Supplier qualification and API handling protocols 

• Inspection readiness assessments and mock audits 

Our approach blends regulatory rigor with operational pragmatism—ensuring that compliance is not just achieved, but sustained. 

We also support clients in addressing common operational challenges such as temperature excursions, inaccurate storage mapping, insufficient route-risk assessments, poor supplier oversight, inconsistent documentation, and gaps in logistics provider qualification. 

To support continuous improvement, we establish GDP-aligned KPIs including temperature excursion rates, delivery performance metrics, CAPA closure timelines, training effectiveness, supplier audit completion rates, and recall response times. These KPIs help organizations monitor performance and demonstrate supply chain maturity. 

Global Alignment of GDP 

As supply chains globalize, organizations must align EU GDP with WHO GDP guidelines, U.S. DSCSA serialization and traceability requirements, MHRA expectations post-Brexit, and regional regulations in Asia-Pacific, LATAM, and the Middle East. TSQ&E provides end-to-end guidance to harmonize global distribution operations, prevent compliance gaps, and support market expansion. 

Conclusion 

GDP is more than a checklist—it’s a framework for trust, safety, and accountability. As regulatory flexibilities sunset and inspection regimes intensify, TS Quality & Engineering stands ready to guide organizations through the developing landscape of medicinal distribution. Whether you’re a manufacturer, importer, or distributor, our expertise ensures your supply chain remains compliant, resilient, and globally credible. 

For organizations seeking to strengthen distribution readiness, TSQ&E offers GDP pre-audit assessments, transportation and warehouse qualification support, and end-to-end distribution compliance strategies to ensure full alignment with EU and international standards